Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20597734 | 0.77 | CASR (0.40) | ALDH1A1L3MBTL1 | |
| SCHEMBL3289198 | 0.76 | SMN1; SMN2 (0.43) | SMN1; SMN2NPC1RAB9AALDH1A1HSD17B10 | |
| SCHEMBL2057008 | 0.76 | ALDH1A1 (0.40) | ALDH1A1HSD17B10HPGDTDP1 | |
| SCHEMBL5548679 | 0.76 | PDPK1 (0.32) | NPC1RAB9AALDH1A1MAPTGAA | |
| SCHEMBL4009888 | 0.76 | SMN1; SMN2 (0.32) | SMN1; SMN2NPC1RAB9AALDH1A1HPGD | |
| SCHEMBL212081 | 0.76 | — | — | |
| SCHEMBL6197116 | 0.76 | SMN1; SMN2 (0.40) | SMN1; SMN2NPC1RAB9AALDH1A1HSD17B10 | |
| SCHEMBL9163875 | 0.76 | ALDH1A1 (0.33) | SMN1; SMN2NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL10422668 | 0.72 | CASR (0.33) | — | |
| SCHEMBL5540904 | 0.72 | KDM4E (0.42) | SMN1; SMN2NPC1RAB9AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103275091-A | Ixabepilone total synthesis | SHENZHEN JATIE PHARMACEUTICAL CO LTD | 2013-09-04 | — | — | CN | claimed |
| CN-1732172-A | Epothilone derivatives | NOVARTIS AG (CH) | 2006-02-08 | — | — | CN | claimed |
| US-20060014796-A1 | Epothilone derivatives | DENNI-DISCHERT DONATIENNE | 2006-01-19 | — | — | US | claimed |
| EP-1581536-A2 | EPOTHILONE DERIVATIVES | Novartis AG (CH) | 2005-10-05 | — | — | EP | claimed |
| WO-2004056832-A2 | EPOTHILONE DERIVATIVES | NOVARTIS AG (CH) | 2004-07-08 | — | — | WO | claimed |
| US-11866411-B2 | Therapeutic compounds and compositions | Agios Pharmaceutical, Inc. (US) | 2024-01-09 | — | — | US | disclosed |
| EP-3406251-B1 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY | AGIOS PHARMACEUTICALS INC (US) | 2023-11-29 | — | — | EP | disclosed |
| US-11793806-B2 | Pyruvate kinase activators for use in therapy | AGIOS PHARMACEUTICALS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-RE49582-E1 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| CN-114432312-A | Pyruvate kinase activators for therapy | 安吉奥斯医药品有限公司 | 2022-05-06 | — | — | CN | disclosed |
| CN-108451955-B | Pyruvate kinase activators for therapy | 安吉奥斯医药品有限公司 | 2022-02-01 | — | — | CN | disclosed |
| US-20210220351-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY | AGIOS PHARMACEUTICALS, INC. | 2021-07-22 | — | — | US | disclosed |
| EP-1581536-A2 | EPOTHILONE DERIVATIVES | Novartis AG (CH) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004056832-A2 | EPOTHILONE DERIVATIVES | NOVARTIS AG (CH) | 2004-07-08 | — | — | WO | disclosed |
| US-6268514-B1 | TREATING INDUSTRIAL MATERIALS WITH NITROETHANE COMPOUND FOR PROTECTING AGAINST ATTACK AND DESTRUCTION BY MICROORGANISMS | BASF AKTIENGESELLSCHAFT (DE) | 2001-07-31 | — | — | US | disclosed |
| EP-0347766-B1 | 4,5,7,8-Tetrahydro-6H-thiazolo[5,4-d]azepines, their preparation and their use as medicaments | THOMAE GMBH DR K (DE) | 1994-05-25 | — | — | EP | disclosed |
| US-5068325-A | Dopaminergic systems as hypotensives, sedatives, antitussives and/or antiphlogistics | KARL THOMAE GMBH (DE) | 1991-11-26 | — | — | US | disclosed |
| EP-0347766-A2 | 4,5,7,8-Tetrahydro-6H-thiazolo[5,4-d]azepines, their preparation and their use as medicaments | Dr. Karl Thomae GmbH (DE) | 1989-12-27 | — | — | EP | disclosed |
| US-4528331-A | Sealant compositions having, as an essential component, hydrogenated polybutadiene as network polymer | THE FIRESTONE TIRE & RUBBER COMPANY (US) | 1985-07-09 | — | — | US | disclosed |
| US-4445562-A | PNEUMATIC TIRES | THE FIRESTONE TIRE & RUBBER COMPANY (US) | 1984-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11793806-B2 | Pyruvate kinase activators for use in therapy | PCK1, PDK3, PDK2 | SMN1; SMN2 2747/4885NPC1 1451/4885RAB9A 4648/4885 |
| US-20210220351-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY | PCK1, PDK3, PDK2 | SMN1; SMN2 2747/4885NPC1 1451/4885RAB9A 4648/4885 |
| US-20060014796-A1 | Epothilone derivatives | CYP4A11, CYP51A1, EPOR | SMN1; SMN2 3644/4885NPC1 1196/4885RAB9A 3289/4885 |
| US-11866411-B2 | Therapeutic compounds and compositions | PDK1, PDK2, PDK3 | SMN1; SMN2 3641/4885NPC1 2350/4885RAB9A 3605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.